Lenalidomide [Leavdo®]
202003096MIPC
Phase 2 small_molecule active
Quick answer
Lenalidomide [Leavdo®] for Antibiotics-unresponsive MALT Lymphoma is a Phase 2 program (small_molecule) at Hospital Authority, Hong Kong with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Hospital Authority, Hong Kong
- Indication
- Antibiotics-unresponsive MALT Lymphoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active